{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:10:26Z","timestamp":1756167026430,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003400","name":"Ontario Ministry of Research, Innovation and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101156","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T02:34:39Z","timestamp":1699583679000},"page":"101156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6818-3825","authenticated-orcid":false,"given":"Nigel","family":"Blackwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Zetzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Trevino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101156_bib1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noy009","article-title":"Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis","volume":"20","author":"Louvrier","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omtm.2023.101156_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/humu.20679","article-title":"Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas","volume":"29","author":"Sestini","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtm.2023.101156_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ijc.31052","article-title":"The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors","volume":"142","author":"de Gooijer","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omtm.2023.101156_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-020-00967-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of selumetinib","volume":"60","author":"Campagne","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omtm.2023.101156_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00280-009-1068-8","article-title":"Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents","volume":"65","author":"O'Reilly","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omtm.2023.101156_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J.\u00a0Neuro Oncol."},{"key":"10.1016\/j.omtm.2023.101156_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000496984","article-title":"Everolimus and bevacizumab in the management of recurrent, progressive intracranial NF2 mutated meningioma","volume":"12","author":"Mathew Thomas","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.omtm.2023.101156_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omtm.2023.101156_bib9","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","article-title":"Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma","volume":"10","author":"Sagers","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2023.101156_bib10","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.101156_bib11","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1158\/2159-8290.CD-15-0330","article-title":"NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition","volume":"5","author":"Garcia-Rendueles","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omtm.2023.101156_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtm.2023.101156_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/neuonc\/noz151","article-title":"MEK\/MELK inhibition and blood\u2013brain barrier deficiencies in atypical teratoid\/rhabdoid tumors","volume":"22","author":"Meel","year":"2020","journal-title":"Neuro Oncol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012300195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012300195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T16:12:14Z","timestamp":1756138334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012300195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":13,"alternative-id":["S232905012300195X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101156","relation":{},"ISSN":["2329-0501"],"issn-type":[{"type":"print","value":"2329-0501"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101156"}}